Reprogramming tumor-associated macrophages using STING or TLR agonists: a promising strategy to enhance immunotherapy...

Area of Science:

• Oncology
• Immunology
• Nanotechnology

Background:

• Hormone-dependent cancers (e.g., breast, prostate) present challenges due to hormone signaling, immune evasion, and therapeutic resistance.
• Endocrine therapies face resistance, leading to cancer progression. The tumor microenvironment (TME) is often immunosuppressive, hindering treatments like immune checkpoint inhibitors.
• Tumor-associated macrophages (TAMs) are key players in TME immunosuppression and can impair endocrine therapy efficacy.

Purpose of the Study:

• To investigate a novel therapeutic strategy for hormone-dependent cancers by reprogramming TAMs.
• To evaluate the synergistic potential of TAM reprogramming combined with standard endocrine therapy.

Main Methods:

• Development of lipid nanoparticles decorated with antibodies targeting folate receptor-beta on perivascular TAMs.
• Loading nanoparticles with a STING agonist (cGAMP) to reprogram TAMs.
• Preclinical testing in murine models of prostate cancer, assessing combination therapy with androgen deprivation therapy.

Main Results:

• The developed nanoparticle-based therapy successfully reprogrammed TAMs in preclinical models.
• Significant synergistic activity was observed when this approach was combined with androgen deprivation therapy in prostate cancer models.
• This strategy demonstrated potential to restore anti-tumor immunity and enhance treatment efficacy.

Conclusions:

• TAM reprogramming represents a promising strategy to overcome resistance in hormone-dependent cancers.
• Combining targeted TAM reprogramming with endocrine therapy offers a synergistic approach for improved cancer treatment.
• This research highlights a novel therapeutic avenue for managing complex oncological challenges.